We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Expert Panel Recommends Ardelyx’s CKD Drug Despite Misgivings
FDA Expert Panel Recommends Ardelyx’s CKD Drug Despite Misgivings
An FDA advisory committee voted 9-4 yesterday in favor of Ardelyx’s Xphozah (tenapanor) for adults with chronic kidney disease (CKD) who are on dialysis, despite some concerns over the drug’s efficacy.